A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia GS-US-312-0123
Clinical Trial Grant
Awarded By
Gilead Sciences, Inc.
Start Date
August 11, 2014
End Date
October 11, 2017
Awarded By
Gilead Sciences, Inc.
Start Date
August 11, 2014
End Date
October 11, 2017